Coegin Pharma AB ("Coegin") today announces further details on the launch of a new high-performance cosmetic scalp serum developed to optimize the scalp environment. The product expands the Follicopeptide portfolio and strengthens the Company's commercialization strategy by broadening the offering beyond the Follicopeptide gel serum. The addition supports increased market penetration, stronger partner offerings and improved long-term revenue potential, while maintaining capital efficiency and operational focus.

The new scalp serum is designed to function both as a high-performance stand-alone cosmetic hair product and as an integrated part of the Follicopeptide portfolio. The carefully selected combination of scientifically validated cosmetic actives help prepare and condition the scalp, enhancing and accelerating the overall user experience of Follicopeptide Gel Serum. At the same time, the product delivers meaningful stand-alone cosmetic performance, allowing seamless integration into existing haircare routines. It broadens the addressable customer base and increases opportunities for use across different settings, enhancing the overall value proposition for distributors, clinics and retailers.

The portfolio expansion reflects Coegin's disciplined growth strategy: building a broader, scalable product ecosystem around its proprietary peptide platform. This approach maximizes commercial reach, supports accelerated revenue growth and increased recurring volumes, without adding operational complexity. 

From a commercial perspective, the additional product increases shelf presence, strengthens cross-selling opportunities and supports higher lifetime value per customer. A broader portfolio is a key success factor in both professional and consumer channels, facilitating onboarding of new partners and improving visibility in competitive retail environments.

Production of the new product will be fully outsourced to an established cosmetic manufacturing partner in Denmark. First delivery to Coegin is expected in April, and the product is planned to be ready for launch in Q2 -26. This structure enables rapid and scalable market introduction while ensuring high quality and regulatory compliance.

The company has already received clear interest from both existing and prospective commercial partners to include the product in upcoming launches and portfolio expansions, supporting confidence in the market potential ahead of launch. Importantly, the model allows Coegin to maintain full operational focus on scaling in-house production of Follicopeptide Gel Serum, where demand continues to grow.

"With this launch, we are broadening the commercial footprint of the Follicopeptide portfolio in a scalable and capital-efficient way," says Jens Eriksson, CEO of Coegin Pharma. "Expanding the portfolio with additional products increases our strategic flexibility, strengthens our partner proposition and supports long-term value creation, while we continue to scale our core technology to meet rising global demand."

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com 

Attached files